Radiation plus immune therapy: new hope for mesothelioma patients
NCT ID NCT02959463
Summary
This early-stage trial is testing whether adding the immunotherapy drug pembrolizumab after radiation therapy is safe for people with a type of lung cancer called malignant pleural mesothelioma. The study involves 24 patients who have not had their lung removed. Researchers want to see if this two-step approach—radiation followed by a drug that helps the immune system fight cancer—is tolerable and might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MALIGNANT MESOTHELIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.